Table: q1_q4_2022_prescription_drugs_intro_to_market , manufacturer_name like N*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
NextWave Pharmaceuticals, Inc.	24478010201	Dyanavel XR (amphetamine) Suspension 2.5gm/mL 464mL Bottle	2022-09-07	1341.9900	None	1	26000	None	None	None	None	None	None	The NDA approval is in the name of TRIS Pharma, parent of Nextwave Pharma. This is not an acquisition.	None
Nobelpharma America, LLC	73683010110	HYFTOR (sirolimus topical gel) 0.2%	2022-08-22	1750.0000	None	1	30000	None	1	None	None	None	None	Nobelpharma America, LLC considers the process of assessing and developing a marketing and pricing plan to be a trade secret using confidential information and cannot release this data into the public domain.	None
Novartis	00078102884	Vijoice (alpelisib) 125 mg 28 tablets	2022-04-05	32500.0000	Novartis considered many factors in determining the price of Vijoice. Vijoice is a treatment for adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowths and blood vessel anomalies impacting an estimated 14 people per million. We priced in parity to other branded treatments in this therapeutic area and are focused on access to Vijoice for this patient population.	None	4800	1	1	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.	None
Novartis	00078103502	Vijoice (alpelisib) 250 mg 56 tablets	2022-04-05	32500.0000	Novartis considered many factors in determining the price of Vijoice. Vijoice is a treatment for adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowths and blood vessel anomalies impacting an estimated 14 people per million. We priced in parity to other branded treatments in this therapeutic area and are focused on access to Vijoice for this patient population.	None	4800	1	1	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.	None
Novartis	00078102184	Vijoice (alpelisib) 50 mg 28 tablets	2022-04-05	32500.0000	Novartis considered many factors in determining the price of Vijoice. Vijoice is a treatment for adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. Vijoice is the first FDA-approved treatment for PROS, a spectrum of rare conditions characterized by overgrowths and blood vessel anomalies impacting an estimated 14 people per million. We priced in parity to other branded treatments in this therapeutic area and are focused on access to Vijoice for this patient population.	None	4800	1	1	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.	None
Novugen Pharma USA LLC	82293000210	ABIRATERONE ACETATE	2022-08-15	4219.5400	This is a generic drug that will be distributed through typical generic channels such as wholesalers, distributors and retail pharmacy chains. Pricing was established by reviewing competitive generic products and aligning WAC prices with the lowest available price for the product.	None	350	None	None	None	None	None	None	None	None